Por favor, use este identificador para citar o enlazar este ítem: https://hdl.handle.net/11000/30950

Eligibility criteria for Menopausal Hormone Therapy (MHT): a position statement from a consortium of scientific societies for the use of MHT in women with medical conditions. MHT Eligibility Criteria Group

Título :
Eligibility criteria for Menopausal Hormone Therapy (MHT): a position statement from a consortium of scientific societies for the use of MHT in women with medical conditions. MHT Eligibility Criteria Group
Autor :
Mendoza, Nicolás
Ramírez, Isabel
de La Viuda, Esther
Coronado, Pluvio
Baquedano, Laura
Llanera, Plácido
Nieto, Verónica
Onero, Borja
Sánchez Méndez, Sonia
Álvarez de Frutos, Visitación
Andraca, Leire
Barriga, Patricio
Benítez, Zully
Bombas, Teresa
Canelo, María Jesús
Cano, Antonio
Castelo Branco, Camil
Correa, Marta
Doval, José Luis
Fasero, María
Fiol, Gabriel
Garello, Néstor C.
Genazzani, Andrea R.
Gómez, Ana Isabel
Gómez, María Ángeles
González, Silvia
Goulis, Dimitrios G.
Guinot, Misericordia
Rolando Hernández, Luis
Herrero, Sonia
Iglesias, Eva
Jurado, Ana Rosa
Lete, Iñaki
Lubián, Daniel
Martínez, Milagros
Nieto, Aníbal
Nieto, Laura
Palacios, Santiago
Pedreira, Milagros
Pérez Campos, Ezequiel
Plá, María Jesús
Presa, Jesús
Quereda Seguí, Francisco José
Ribes, Miriam
Romero, Pablo
Roca, Beatriz
Sánchez Capilla, Antonio
Sánchez Borrego, Rafael
Santaballa, Ana
Santamaría, Amparo
Simoncini, Tommaso
Tinahones, Fancisco
Calaf, Joaquín
Editor :
Elsevier [Commercial Publisher]
Departamento:
Departamentos de la UMH::Salud Pública, Historia de la Ciencia y Ginecología
Fecha de publicación:
2022-12
URI :
https://hdl.handle.net/11000/30950
Resumen :
This project aims to develop eligibility criteria for menopausal hormone therapy (MHT). The tool should be similar to those already established for contraception A consortium of scientific societies coordinated by the Spanish Menopause Society met to formulate recommendations for the use of MHT by women with medical conditions based on the best available evidence. The project was developed in two phases. As a first step, we conducted 14 systematic reviews and 32 metanalyses on the safety of MHT (in nine areas: age, time of menopause onset, treatment duration, women with thrombotic risk, women with a personal history of cardiovascular disease, women with metabolic syndrome, women with gastrointestinal diseases, survivors of breast cancer or of other cancers, and women who smoke) and on the most relevant pharmacological interactions with MHT. These systematic reviews and metanalyses helped inform a structured process in which a panel of experts defined the eligibility criteria according to a specific framework, which facilitated the discussion and development process. To unify the proposal, the following eligibility criteria have been defined in accordance with the WHO international nomenclature for the different alternatives for MHT (category 1, no restriction on the use of MHT; category 2, the benefits outweigh the risks; category 3, the risks generally outweigh the benefits; category 4, MHT should not be used). Quality was classified as high, moderate, low or very low, based on several factors (including risk of bias, inaccuracy, inconsistency, lack of directionality and publication bias). When no direct evidence was identified, but plausibility, clinical experience or indirect evidence were available, "Expert opinion" was categorized. For the first time, a set of eligibility criteria, based on clinical evidence and developed according to the most rigorous methodological tools, has been defined. This will provide health professionals with a powerful decision-making tool that can be used to manage menopausal symptoms.
Palabras clave/Materias:
Menopausal hormone therapy
menopause
Tipo documento :
application/pdf
Derechos de acceso:
info:eu-repo/semantics/openAccess
Attribution-NonCommercial-NoDerivatives 4.0 Internacional
DOI :
https://doi.org/10.1016/j.maturitas.2022.08.008
Aparece en las colecciones:
Artículos Salud Pública, Historia de la Ciencia y Ginecología



Creative Commons La licencia se describe como: Atribución-NonComercial-NoDerivada 4.0 Internacional.